ARTICLE | Company News
Diatos, Gilead deal
May 15, 2006 7:00 AM UTC
GILD granted Diatos exclusive worldwide development and commercialization rights to DaunoXome liposomal daunorubicin, which is approved to treat AIDS/HIV-related Kaposi's sarcoma. GILD will receive u...